Navigation Links
Regado Biosciences, Inc. to Present at the Oppenheimer 23rd Annual Healthcare Conference in New York, NY
Date:12/5/2012

>ABOUT REG1, REG2 and REG3 
Regado's lead program, the anticoagulant system REG1, consists of two agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (pegnivacogin) with the second being its complementary active control agent (anivamersen).  Anivamersen can be used to selectively reverse (completely or partially) the anticoagulant effect of pegnivacogin.  REG1, recently completing phase 2b (the RADAR trial), is intended for application in arterial thrombosis indications, such as Acute Coronary Syndrome patients undergoing Percutaneous Coronary Intervention.  A clinical program in Open Heart Surgery [including coronary artery bypass grafting (CABG) and valve repair/replacement] is also under development.  REG2, Regado's second product candidate, consists of a subcutaneously administered depot formulation of pegnivacogin paired with the IV bolus formulation of anivamersen.  REG2 has completed single escalating dose phase 1 clinical testing (the first successful subcutaneous application of an aptamer in humans) and is planned to be studied in a multiple escalating dose clinical trial.  It is intended for use in venous thrombosis indications such as venous thromboembolism (VTE) prophylaxis in patients undergoing abdominal surgery.  REG3, Regado's third program, consists of a specific GPVI inhibitor and its active control agent (RB571 and RB515, respectively).  REG3 is planned to enter phase 1 human clinical testing shortly and will be indicated for antiplatelet therapy such as in treating diabetic vasculopathies.

ABOUT APTAMERS
Pegnivacogin is a member of a class of compounds called aptamers.  Aptamers are single stranded oligonucleotides that adopt a specific conformation enabling direct, specific inhibition of the targeted protein.   A key unique feature of aptamers derives from the fact that they are formed from nucleic acids. 
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences, Inc. to Present at the UBS Global Life Sciences Conference 2012 in New York, NY
2. Regado Biosciences, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference in Boston, MA
3. Regado Biosciences, Inc. to Present at the 2012 Wedbush PacGrow Life Sciences Conference in New York, NY
4. Pressure BioSciences, Inc. to Discuss Third Quarter 2012 Financial Results and Provide Business Update
5. Pressure BioSciences, Inc. Reports 70% Revenue Growth for Second Consecutive Quarter
6. Pressure BioSciences, Inc. to Discuss Second Quarter 2012 Financial Results and Provide Business Update
7. Founded by Enlight Biosciences, KNODE partners with AstraZeneca and Other Partners
8. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
9. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
10. Optimer Pharmaceuticals to Present at 23rd Annual Oppenheimer Healthcare Conference
11. PAREXEL International To Present At Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/256szd/corporate ... Reputation of Pharma in 2014 - a Perspective of ... to their offering. For the first time, ... corporate reputation of the pharmaceutical industry held by patient ... views of patient organisations representing all therapy areas. ...
(Date:4/16/2015)... April 16, 2015 Mindray Medical International ... and marketer of medical devices worldwide, announced today ... Exchange Commission an Annual Report on Form 20-F that ... 31, 2014. An electronic version of Mindray,s Annual ... investor relations website at  http://ir.mindray.com  or  http://www.sec.gov . ...
(Date:4/16/2015)... -- Mallinckrodt plc (NYSE: MNK ), a ... has completed its acquisition of Ikaria, Inc. at ... Ikaria acquisition extends Mallinckrodt,s footprint in the hospital ... care with INOMAX ® (inhaled nitric oxide), ... patient population. It also accelerates Mallinckrodt,s rapid growth ...
Breaking Medicine Technology:Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 2Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 3Mindray Files Annual Report on Form 20-F with the U.S. Securities and Exchange Commission 2Mallinckrodt Completes Acquisition Of Ikaria 2Mallinckrodt Completes Acquisition Of Ikaria 3Mallinckrodt Completes Acquisition Of Ikaria 4Mallinckrodt Completes Acquisition Of Ikaria 5
... 2, 2011 Nile Therapeutics, Inc. (Nasdaq: ... novel therapeutics for heart failure patients, today announced that, ... determination from the NASDAQ Listing Qualifications Panel (the "Panel") ... for an extension to remain listed on The NASDAQ ...
... 2011 Pacira Pharmaceuticals, Inc., (Nasdaq: ... announced that positive results from its Phase 1 ... patients with moderate hepatic impairment, will be presented ... and Therapeutics (ASCPT) 112th Annual Meeting in Dallas, ...
Cached Medicine Technology:Nile Therapeutics Receives Positive NASDAQ Panel Decision 2Nile Therapeutics Receives Positive NASDAQ Panel Decision 3Pacira Pharmaceuticals' EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting 2Pacira Pharmaceuticals' EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting 3
(Date:4/17/2015)... 17, 2015 As a board-certified orthopedic ... new offering of platelet-rich plasma (PRP) and ... is known for its world-class care of injury-caused ... surgical experience lacking in many other physicians offering regenerative ... are utilized for pain management and rehabilitation. Dr. Meier ...
(Date:4/17/2015)... 17, 2015 Baptist Health and The ... a partnership agreement designed to transform oncology care in ... have agreed to create a joint cancer program to ... translational research. Baptist MD Anderson Cancer Center is anticipated ... single destination for highly coordinated, multidisciplinary cancer care for ...
(Date:4/17/2015)... 2015 Connie Casad, M.D., a well-known ... advocate with 30 years of practice experience in Dallas, ... level of service for her patients with the availability ... recommended wellness books with a brief synopsis on each ... her interest in providing this service, Dr. Casad said, ...
(Date:4/17/2015)... 2015 Oxytocin is a ... and thought to help mothers bond to their newborn, ... substantiate this, new studies performed, at NYU Langone Medical ... reported by Medical News Today on April 16, 2015, ... maternal social behavior. The study reveals that, when oxytocin ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Ticket Down is a ... their 2015 Summer Tour. , The life of last-minute show announcements ... the popular group perform during the early part of 2015, but ... Will Wait,” “Little Lion Man,” “The Cave,” and “Believe,” will perform ... on June 2 at MCU Park at Coney Island in Brooklyn, ...
Breaking Medicine News(10 mins):Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 3Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 3Health News:Connie Casad, M.D. Provides Patients Recommended List of Wellness Books on Website 2Health News:Oxytocin Now Found to Help Diet Doc Patients Whose Weight Has Gotten out of Control Due to Emotional Eating Disorders 2Health News:Oxytocin Now Found to Help Diet Doc Patients Whose Weight Has Gotten out of Control Due to Emotional Eating Disorders 3Health News:Mumford and Sons Tickets in Clarkston/Detroit, Raleigh, Columbia/Baltimore, Chicago, Mansfield/Boston, Brooklyn, Calgary and Edmonton Now On Sale 2
... Teenagers and young adults with cancer are being ... trials with the 13-24 age group in mind and ... to those trials that do exist, according to new ... University College Hospital, London, told Teenage Cancer Trust,s Fifth ...
... June 2008 A 115-year-old woman who remained mentally ... with little or no evidence of Alzheimer,s disease, according ... of Aging ( http://neurobiologyofaging.org/ ). , The findings question ... dementia will inevitably develop, if people live long enough. ...
... specialist nurse clinic rather than a consultant-led clinic for ... and good symptom management, according to a paper in ... , And because the clinical nurse specialist was ... consultations without referring issues to the consultant, patients also ...
... Gentag, Inc. and MacroArray,Technologies, LLC have entered into ... Gentag,s cell phone communication,technology and MacroArray,s urine diagnostic ... males are at risk of developing prostate cancer, ... order to simplify and expand,the use of low ...
... ATS Medical, Inc.,(Nasdaq: ATSI ), manufacturer ... services, today noted that several key opinion ... Medical products and related,procedures during the scientific ... Invasive Cardiothoracic Surgery (ISMICS) annual,meeting in Boston., ...
... (NASDAQ: QLTI; TSX:,QLT) announced today that QLT USA, ... purchase agreement with Allergan Sales, LLC, a,wholly-owned subsidiary ... fully divest QLT,s,worldwide rights to Aczone(R), a prescription ... for the treatment of acne vulgaris. Under the,terms ...
Cached Medicine News:Health News:Organizers of cancer clinical trials are neglecting teenagers and young adults 2Health News:Organizers of cancer clinical trials are neglecting teenagers and young adults 3Health News:World's oldest woman had normal brain 2Health News:Specialist nurses can play a key role in supporting patients having radiotherapy 2Health News:Specialist nurses can play a key role in supporting patients having radiotherapy 3Health News:Gentag, Inc. and MacroArray Technologies Join Forces 2Health News:ATS Medical Products Prominently Featured in International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) Scientific Presentations 2Health News:ATS Medical Products Prominently Featured in International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) Scientific Presentations 3Health News:QLT announces agreement to sell Aczone(R) to Allergan for approximately US$150 million 2Health News:QLT announces agreement to sell Aczone(R) to Allergan for approximately US$150 million 3Health News:QLT announces agreement to sell Aczone(R) to Allergan for approximately US$150 million 4Health News:QLT announces agreement to sell Aczone(R) to Allergan for approximately US$150 million 5
The workhorse electric system....
... The BD Safety Knife with BD Xstar ... shield that protects the blade in prodedure ... is based on a grind-less process for ... yields outstanding sharpness and consistency. The ...
... Safety Knife with BD Xstar Blade includes ... protects the blade in prodedure and handling. ... on a grind-less process for manufacturing surgical ... sharpness and consistency. The arch style, ...
... The BD Safety Knife with BD ... retractable shield that protects the blade in ... technology is based on a grind-less process ... process yields outstanding sharpness and consistency. ...
Medicine Products: